genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.
The event will be held on Friday, 12 June 2020 at 2 pm. Please register your interest at https://voxmarkets.brand.live/c/genedrive-plc .
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.
The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned